• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Personalized Depression Treatment

Traditional therapy and medication don't work for a majority of people suffering from depression. Personalized treatment may be the solution.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into customized micro-interventions designed to improve mental health. We looked at the best-fitting personal ML models for each individual, using Shapley values to determine their feature predictors. This revealed distinct features that were deterministically changing mood over time.

Predictors of Mood

Depression is among the leading causes of mental illness.1 However, only half of those suffering from the disorder receive treatment1. To improve the outcomes, doctors must be able to recognize and treat patients with the highest likelihood of responding to specific treatments.

The ability to tailor depression treatments is one way to do this. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants were awarded that total more than $10 million, they will use these tools to identify biological and behavioral predictors of the response to antidepressant medication and psychotherapy.

To date, the majority of research on predictors for depression treatment effectiveness has been focused on clinical and sociodemographic characteristics. These include demographics such as age, gender and education as well as clinical characteristics such as symptom severity, comorbidities and biological markers.

While many of these variables can be predicted by the information in medical records, very few studies have used longitudinal data to explore the causes of mood among individuals. A few studies also take into consideration the fact that mood can vary significantly between individuals. Therefore, it is important to develop methods that allow for the determination and quantification of the individual differences in mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can identify different patterns of behavior and emotions that are different between people.

In addition to these modalities, the team also developed a machine-learning algorithm to model the changing factors that determine a person's depressed mood. The algorithm integrates the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely across individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world1, but it is often misdiagnosed and untreated2. In addition the absence of effective interventions and stigmatization associated with depressive disorders prevent many individuals from seeking help.

To assist in individualized treatment, it is essential to determine the predictors of symptoms. Current prediction methods rely heavily on clinical interviews, which are not reliable and only detect a few characteristics that are associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements. They also capture a wide variety of unique behaviors and activity patterns that are difficult to capture through interviews.

The study included University of California Los Angeles (UCLA) students with mild to severe depression treatment brain stimulation symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 developed under the UCLA Depression Grand Challenge. Participants were referred to online assistance or medical care based on the severity of their depression. Patients with a CAT DI score of 35 65 were allocated online support via the help of a peer coach. those who scored 75 were sent to in-person clinical care for psychotherapy.

At the beginning, participants answered the answers to a series of questions concerning their personal characteristics and psychosocial traits. The questions included age, sex and education, marital status, financial status and whether they were divorced or not, current suicidal thoughts, intent or attempts, as well as how often they drank. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale of 0-100. The CAT-DI test was conducted every two weeks for participants who received online support, and weekly for those who received in-person support.

Predictors of the Reaction to Treatment

A customized treatment for depression is currently a top research topic and many studies aim at identifying predictors that help clinicians determine the most effective medications for each individual. In particular, pharmacogenetics identifies genetic variations that affect the way that the body processes antidepressants. This lets doctors select the medication that are likely to be the most effective for every patient, minimizing time and effort spent on trials and errors, while avoiding any side negative effects.

Another promising approach is building prediction models using multiple data sources, including the clinical information with neural imaging data. These models can be used to determine the most effective combination of variables predictive of a particular outcome, like whether or not a particular medication to treat anxiety and depression, clashofcryptos.trade, will improve the mood and symptoms. These models can also be used to predict the patient's response to alternative treatment for depression and anxiety that is already in place which allows doctors to maximize the effectiveness of their current therapy.

A new era of research utilizes machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables to improve predictive accuracy. These models have been demonstrated to be useful in predicting the outcome of treatment, such as response to antidepressants. These approaches are gaining popularity in psychiatry, and it is expected that they will become the norm for future clinical practice.

In addition to the ML-based prediction models, research into the underlying mechanisms of depression continues. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that individual depression treatment without medication treatment will be focused on therapies that target these neural circuits to restore normal function.

Internet-delivered interventions can be a way to achieve this. They can offer an individualized and tailored experience for patients. A study showed that a web-based program improved symptoms and led to a better quality of life for MDD patients. A randomized controlled study of a customized treatment for depression revealed that a substantial percentage of participants experienced sustained improvement as well as fewer side negative effects.

Predictors of Side Effects

In the treatment of depression treatment without meds, one of the most difficult aspects is predicting and determining the antidepressant that will cause very little or no side negative effects. Many patients experience a trial-and-error method, involving various medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics is an exciting new method for an efficient and specific approach to choosing antidepressant medications.

There are a variety of predictors that can be used to determine the antidepressant that should be prescribed, including genetic variations, phenotypes of patients like gender or ethnicity and co-morbidities. To identify the most reliable and valid predictors for a particular treatment, controlled trials that are randomized with larger numbers of participants will be required. This is because it may be more difficult to detect interactions or moderators in trials that comprise only one episode per person instead of multiple episodes spread over time.

Additionally to that, predicting a patient's reaction will likely require information about comorbidities, symptom profiles and the patient's own experience of tolerability and effectiveness. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

Many issues remain to be resolved when it comes to the use of pharmacogenetics to treat depression. First it is necessary to have a clear understanding of the underlying genetic mechanisms is required as well as a clear definition of what constitutes a reliable predictor for treatment response. In addition, ethical issues, such as privacy and the ethical use of personal genetic information must be carefully considered. Pharmacogenetics could, in the long run, reduce stigma surrounding mental health treatments and improve the outcomes of treatment. But, like any approach to psychiatry careful consideration and planning is essential. For now, the best method is to provide patients with a variety of effective depression medication options and encourage them to speak openly with their doctors about their concerns and experiences.